Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLAST: Liposomal Alendronate for In-Stent Restenosis
NCT00739466Phase 2Completed
- Sponsor
- BioRest
- Start
- Sep 2008
- Primary completion
- Dec 2015
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Liposomal alendronate in in-stent restenosis (ISR) (3 arms), sponsored by BioRest. Primary endpoint: In-stent late loss at 6 months. Started Sep 2008; status: completed.
02
Drugs
Liposomal alendronate
03
Conditions
in-stent restenosis (ISR)
Beyond the preview
Go deeper on NCT00739466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00739466.